JW (Cayman) Therapeutics Co (HKSE:02126) Debt-to-EBITDA : N/A (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

JW (Cayman) Therapeutics Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$132.4 Mil. JW (Cayman) Therapeutics Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$216.3 Mil. JW (Cayman) Therapeutics Co's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$0.0 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for JW (Cayman) Therapeutics Co's Debt-to-EBITDA or its related term are showing as below:

HKSE:02126' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.49 Med: -0.22 Max: -0.08
Current: -0.41

During the past 6 years, the highest Debt-to-EBITDA Ratio of JW (Cayman) Therapeutics Co was -0.08. The lowest was -0.49. And the median was -0.22.

HKSE:02126's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.36 vs HKSE:02126: -0.41

JW (Cayman) Therapeutics Co Debt-to-EBITDA Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Debt-to-EBITDA Chart

JW (Cayman) Therapeutics Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.13

-0.08

-0.23

-0.37

-0.49

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial						-0.18	-0.18	-0.34	-0.53	N/A

Competitive Comparison of JW (Cayman) Therapeutics Co's Debt-to-EBITDA

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Debt-to-EBITDA falls into.

JW (Cayman) Therapeutics Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

JW (Cayman) Therapeutics Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(132.353	+	216.339)	/	-717.242
	=	-0.49

JW (Cayman) Therapeutics Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(132.353	+	216.339)	/	0
	=	N/A

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

JW (Cayman) Therapeutics Co (HKSE:02126) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

JW (Cayman) Therapeutics Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

JWCTF:USA

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines